Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia

Zhang, Li Feng; Tan, Darren Qian Cheng; Jeyasekharan, Anand D.; Hsieh, Kuangwen; Ho, Anh; Ichiyama, Koji; Ye, Min; Pang, Brendan; Ohba, Kihachiro; Liu, Xin; Mel, Sanjay de; Cuong, Bui Khac; Chng, Wee Joo; Ryo, Akihide; Suzuki, Youichi; Yeoh, Khay Guan; Toàn, Nguyễn Lĩnh; Yamamoto, Naoki

doi:10.1016/j.canlet.2014.08.034

Cited by 16 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, combinations of OVs in clinical trials have been limited to one oncolytic Maraba vesiculovirus component combined with an adenoviral vaccine vector (32). Preclinically, a few studies have addressed potential synergy of OV combinations, such as adenovirus and vaccinia (33), mumps and measles virus (34), and Newcastle disease virus (NDV) with reovirus and parvovirus (35). Furthermore, combination of multiple therapeutic modalities including IM with DCs and/or CPI, might provide superior results, and the combined or sequential use of various OVs might boost the therapeutic efficacy by avoiding neutralizing antibody responses elicited against a specific virus strain.…”

Section: Discussionmentioning

confidence: 99%

Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series

Gesundheit¹,

Ben-David

Posen³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) remains an incurable condition, associated with a median survival time of 15 months with best standard of care and 5-year survival rate of <10%. We report on four GBM patients on combination treatment regimens that included oncolytic virus (OV) immunotherapy, who achieved clinical and radiological responses with long-term survival, thus far, of up to 14 years, and good quality of life. We discuss the radiological findings that provide new insights into this treatment, the scientific rationale of this innovative and promising therapy, and considerations for future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series

Gesundheit¹,

Ben-David

Posen³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Several oncolytic viruses are in development, including coxsackievirus A21 for multiple myeloma [9], reovirus for lymphoma [10], and myxoma for acute myeloid leukemia (AML) [11]. Vaccine-strain measles and mumps virus combinations has also led to a synergistic increase in cytotoxicity in myeloid leukemia cells [12]. …”

Section: Discussionmentioning

confidence: 99%

Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment

Lee

Kim

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Pexa-Vec (pexastimogene devacirpvec; JX-594) has emerged as an attractive tool in oncolytic virotherapy. Pexa-Vec demonstrates oncolytic and immunotherapeutic mechanisms of action. But the determinants of resistance to Pexa-Vec are mostly unknown. We treated hemoatologic malignant cells with Pexa-Vec and examined the gene-expression pattern of sensitive and resistant cells. Human myeloid malignant cell lines (RPMI-8226, IM-9, K562, THP-1) and lymphoid cancer cell lines (MOLT4, CCRF-CEM, Ramos, U937) were treated with Pexa-Vec. Pexa-Vec was cytotoxic on myeloid cell lines in a dose-dependent manner, and fluorescent imaging and qPCR revealed that Pexa-Vec expression was low in RAMOS than IM-9 after 24 hrs and 48 hrs of infection. Gene expression profiles between two groups were analyzed by microarray. Genes with at least 2-fold increase or decrease in their expression were identified. A total of 660 genes were up-regulated and 776 genes were down-regulated in lymphoid cancer cell lines. The up- and down-regulated genes were categorized into 319 functional gene clusters. We identified the top 10 up-regulated genes in lymphoid cells. Among them three human genes (LEF1, STAMBPL1, and SLFN11) strongly correlated with viral replication. Up-regulation of PVRIG, LPP, CECR1, Arhgef6, IRX3, IGFBP2, CD1d were related to resistant to Pexa-Vec. In conclusion, lymphoid malignant cells are resistant to Pexa-Vec and displayed up-regulated genes associated with resistance to oncolytic viral therapy. These data provide potential targets to overcome resistance, and suggest that molecular assays may be useful in selecting patients for further clinical trials with Pexa-Vec.

show abstract

“…Previous reports indicated that for some cells, the effect of Ras activation on viral cytotoxicity might be mediated by sensitising the cells to virally induced apoptosis, rather than determining their ability to support viral replication [25]. Other reports showed that cell fusion followed by lysis of cancer cells is a mechanism by which cancer cells are killed by MV [26,27].…”

Section: Enhancement Of Human Melanoma Cell Death Followed By Measlesmentioning

confidence: 99%

The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus

Ammour

Ryabaya

Shchetinina

et al. 2020

Viruses

View full text Add to dashboard Cite

Oncolytic viruses, including live attenuated measles virus (MV) vaccine strains, have recently been shown as promising therapeutic agents against human malignancies. In this study, the oncolytic potential of the attenuated vaccine strain Leningrad-16 (L-16) of MV was evaluated in a panel of human metastatic melanoma cell lines. The L-16 measles virus was shown to replicate within melanoma cells mediating direct cell killing of tumor cells, although all melanoma cell lines varied in regard to their ability to respond to L-16 MV infection, as revealed by the different pattern of the Interferon Stimulated Gene expression, cytokine release and mechanisms of cell death. Furthermore, the statistically significant L-16 measles virus related tumor growth inhibition was demonstrated in a melanoma xenograft model. Therefore, L-16 MV represents an appealing oncolytic platform for target delivery of therapeutic genes along with other attenuated measles virus strains.

show abstract

Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia

Cited by 16 publications

References 38 publications

Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series

Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series

Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment

The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus

Contact Info

Product

Resources

About